Payment overview · 2025
General Payments
$542.82
26 reported records · 13 companies
Healthcare provider profile · identity verified
Vanaja Sureddi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PALM BEACH GARDENS, FL · NPI 1184895286
Verified facts
What the public records show
CMS Open Payments records show Vanaja Sureddi, MD received $542.82 in general payments during 2025 across 26 reported records.
PFIZER INC. accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Paxlovid, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $99.91 | 18.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $85.43 | 15.7% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $58.17 | 10.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.87 | 10.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.70 | 7.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.28 | 6.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.67 | 6.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.41 | 6.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$24.36 | 4.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.62 | 4.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.35 | 3.6% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.10 | 3.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.95 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $505.12 | 24 |
| Education | $37.70 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $75.53 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $58.17 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.87 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $51.31 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $48.60 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.66 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $37.70 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.28 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.67 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 232 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 102 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 104 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 30 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
74 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
232 | 57 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 781 | 249 |
| Levothyroxine Sodium | Levothyroxine Sodium | 659 | 165 |
| Atorvastatin Calcium | Atorvastatin Calcium | 654 | 196 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 596 | 203 |
| Losartan Potassium | Losartan Potassium | 595 | 181 |
| Escitalopram Oxalate | Escitalopram Oxalate | 378 | 109 |
| Simvastatin | Simvastatin | 332 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 329 | 85 |
| Trazodone Hcl | Trazodone Hcl | 321 | 100 |
| Lisinopril | Lisinopril | 306 | 86 |
| Metformin Hcl | Metformin Hcl | 294 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 272 | 89 |
| Eliquis | Apixaban | 232 | 57 |
| Gabapentin | Gabapentin | 204 | 41 |
| Omeprazole | Omeprazole | 197 | 57 |
| Furosemide | Furosemide | 186 | 47 |
| Sertraline Hcl | Sertraline Hcl | 181 | 41 |
| Potassium Chloride | Potassium Chloride | 169 | 42 |
| Methylprednisolone | Methylprednisolone | 145 | 113 |
| Zolpidem Tartrate | Zolpidem Tartrate | 144 | 25 |
| Montelukast Sodium | Montelukast Sodium | 129 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 39 |
| Famotidine | Famotidine | 109 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 35 |
| Valsartan | Valsartan | 106 | 32 |
| Ozempic | Semaglutide | 104 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 31 |
| Azithromycin | Azithromycin | 102 | 85 |
| Jardiance | Empagliflozin | 102 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 29 |
| Buspirone Hcl | Buspirone Hcl | 95 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 34 |
| Carvedilol | Carvedilol | 91 | 30 |
| Nifedipine Er | Nifedipine | 88 | 22 |
| Alprazolam | Alprazolam | 84 | 33 |
| Allopurinol | Allopurinol | 77 | 24 |
| Atenolol | Atenolol | 77 | 24 |
| Cefdinir | Cefdinir | 76 | 62 |
| Trulicity | Dulaglutide | 74 | 13 |
| Alendronate Sodium | Alendronate Sodium | 72 | 23 |
| Temazepam | Temazepam | 63 | suppressed |
| Synthroid | Levothyroxine Sodium | 62 | 19 |
| Ezetimibe | Ezetimibe | 60 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | suppressed |
| Meloxicam | Meloxicam | 59 | 21 |
| Donepezil Hcl | Donepezil Hcl | 57 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 30 |
| Metformin Hcl Er | Metformin Hcl | 52 | 15 |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 12 |
| Cephalexin | Cephalexin | 45 | 40 |
| Glipizide | Glipizide | 45 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 18 |
| Glipizide Er | Glipizide | 41 | 13 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | 11 |
| Bupropion Xl | Bupropion Hcl | 36 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 14 |
| Celecoxib | Celecoxib | 35 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 32 |
| Finasteride | Finasteride | 35 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 23 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 12 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 30 | 26 |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Prednisone | Prednisone | 26 | 15 |
| Valacyclovir | Valacyclovir Hcl | 26 | 11 |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Spironolactone | Spironolactone | 24 | 11 |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Wegovy | Semaglutide | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Nystatin | Nystatin | 20 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 14 |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $542.82 · 26 records | PFIZER INC. | AREXVY, BREZTRI, ELIQUIS, FARXIGA, INTERSTIM, JARDIANCE, MOUNJARO, NURTEC ODT, ONPATTRO, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, XIFAXAN | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error